R. Charles Coombes, MD, PhD; Holly Tovey, MSc; Lucy Kilburn, MSc; et al.
free access
JAMA Oncol. 2021;7(9):1291-1301. doi:10.1001/jamaoncol.2021.2193
This randomized clinical trial evaluates the role of celecoxib as an addition to conventional therapy for women with ERBB2 (formerly HER2)鈥搉egative primary breast cancer.
Frederik Bartels, MD; Mona-Marie Wandrey, MD; Annette Aigner, PhD; et al.
free access
has audio
JAMA Oncol. 2021;7(9):1302-1310. doi:10.1001/jamaoncol.2021.2049
This cross-sectional study assesses the frequency of neuronal autoantibodies in patients with small cell and non鈥搒mall cell lung cancer and examines the association of these autoantibodies with cognitive function.
-
Podcast:
Neuronal Autoantibodies and Cognitive Impairment in Patients With Lung Cancer
Sarah E. S. Leary, MD; Roger J. Packer, MD; Yimei Li, PhD; et al.
free access
JAMA Oncol. 2021;7(9):1313-1321. doi:10.1001/jamaoncol.2021.2224
This randomized clinical trial examines the use of carboplatin and isotretinoin in children with high-risk medulloblastoma, with subgroup analysis by molecular classification.
Heath Skinner, MD, PhD; Chen Hu, PhD; Theodoros Tsakiridis, MD, PhD; et al.
free access
JAMA Oncol. 2021;7(9):1324-1332. doi:10.1001/jamaoncol.2021.2318
This phase 2 randomized clinical trial compares chemoradiation alone vs chemoradiation and metformin for the management of stage III non鈥搒mall cell lung cancer.
-
Invited Commentary
Forging a Path for Metformin Use in Inoperable Locally Advanced Non鈥揝mall Cell Lung Cancer
Chukwuka Eze, MD; Claus Belka, MD, PhD; Farkhad Manapov, MD, PhD
JAMA Oncol
Theodoros Tsakiridis, MD, PhD; Gregory R. Pond, PhD; Jim Wright, MD; et al.
free access
JAMA Oncol. 2021;7(9):1333-1341. doi:10.1001/jamaoncol.2021.2328
This randomized clinical trial examines the use of metformin with chemoradiotherapy and as consolidation treatment in patients being treated for locally advanced non鈥搒mall cell lung cancer.
-
Invited Commentary
Forging a Path for Metformin Use in Inoperable Locally Advanced Non鈥揝mall Cell Lung Cancer
Chukwuka Eze, MD; Claus Belka, MD, PhD; Farkhad Manapov, MD, PhD
JAMA Oncol
Andrew J. Wagner, MD, PhD; Paul L. Severson, PhD; Anthony F. Shields, MD, PhD; et al.
free access
JAMA Oncol. 2021;7(9):1343-1350. doi:10.1001/jamaoncol.2021.2086
This phase 1b/2a nonrandomized clinical trial assesses combination of a type II KIT inhibitor with a conformation-complementary, active-state (type I) KIT inhibitor and broad mutation coverage and global disease control.
Salma K. Jabbour, MD; Ki Hyeong Lee, MD, PhD; Nikolaj Frost, MD; et al.
open access
JAMA Oncol. 2021;7(9):1351-1359. doi:10.1001/jamaoncol.2021.2301
This nonrandomized trial evaluates the treatment outcomes and safety of pembrolizumab plus concurrent chemoradiation therapy in stage III non鈥搒mall cell lung cancer.
Thomas Hatschek, MD; Theodoros Foukakis, MD; Judith Bjöhle, MD; et al.
free access
has audio
JAMA Oncol. 2021;7(9):1360-1367. doi:10.1001/jamaoncol.2021.1932
This randomized clinical trial compares rates of pathologic complete response between standard neoadjuvant therapy of combination docetaxel, trastuzumab, and pertuzumab and trastuzumab emtansine monotherapy in patients with ERBB2-positive breast cancer.
-
Podcast:
Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in ERBB2-Positive Breast Cancer
Scott N. Gettinger, MD; Mary W. Redman, PhD; Lyudmila Bazhenova, MD; et al.
open access
JAMA Oncol. 2021;7(9):1368-1377. doi:10.1001/jamaoncol.2021.2209
This phase 3 randomized clinical trial investigates if the addition of ipilimumab to nivolumab improves the survival outcome of patients with chemotherapy-pretreated immunotherapy-naive squamous cell lung cancer.
Kerstin N. Vokinger, MD, JD, PhD, LLM; Thomas J. Hwang, AB; Paola Daniore, MSc; et al.
free access
online only
JAMA Oncol. 2021;7(9):e212026. doi:10.1001/jamaoncol.2021.2026
This economic evaluation examines the prices of cancer drugs on initial marketing and postlaunch prices and any association with clinical benefit.
Josee-Lyne Ethier, MD, MSc; Danielle Desautels, MD, MSc; Andrew Robinson, MD; et al.
free access
online only
JAMA Oncol. 2021;7(9):e212140. doi:10.1001/jamaoncol.2021.2140
This cohort study describes practice patterns and outcomes associated with use of pertuzumab and trastuzumab emtansine in routine clinical practice.